ArticleThe Journal of experimental medicine2011
The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice.
Article in The Journal of experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 121 citations in OpenAlex.
- Alendronate modulates cytokine responses in healthy young individuals after BCG vaccination.Immunology letters · 2024Trial
- Ex vivo-expanded allogeneic Vδ2 T cells specifically reduce reservoirs of HIV-1 following latency reversal.JCI insight · 2026Article
- CXCR3-mediated natural killer cell infiltration exacerbates white matter injury after intracerebral haemorrhage.Brain : a journal of neurology · 2025Article
- Targeted expansion of cytotoxic T cells using IL-12 and CD137L supplementation enhances antitumor efficacy.Molecular therapy. Oncology · 2025Article
- The role of γδ T cells in flavivirus infections: Insights into immune defense and therapeutic opportunities.PLoS neglected tropical diseases · 2025Review
- Article
- TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice.Emerging microbes & infections · 2024Article
- The interplay of drug therapeutics and immune responses to SARS-CoV-2.Cellular & molecular immunology · 2024Review
- Double-edged sword: γδ T cells in mucosal homeostasis and disease.Experimental & molecular medicine · 2023Review
- Article
- Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and γδ T cell perturbations.JCI insight · 2023Article
- Oral Supplementation with AHCCPathogens (Basel, Switzerland) · 2023Article
- γδ T cells as immunotherapy for malaria: balancing challenges and opportunities.Frontiers in immunology · 2023Article
- Review
- Tissue-resident immunity in the lung: a first-line defense at the environmental interface.Seminars in immunopathology · 2022Review
- Role of hormones in the pregnancy and sex-specific outcomes to infections with respiratory viruses.Immunological reviews · 2022Review
- Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment.Journal for immunotherapy of cancer · 2022Article
- CD137 Costimulation Enhances the Antitumor Activity of Vγ9Vδ2-T Cells in IL-10-Mediated Immunosuppressive Tumor Microenvironment.Frontiers in immunology · 2022Article
- Role of Vγ9vδ2 T lymphocytes in infectious diseases.Frontiers in immunology · 2022Review
- Defying convention in the time of COVID-19: Insights into the role of γδ T cells.Frontiers in immunology · 2022Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are few antiviral drugs for treating influenza, and the emergence of antiviral resistance has further limited the available therapeutic options. Furthermore, antivirals are not invariably effective in severe influenza, such as that caused by H5N1 viruses. Thus, there is an urgent need to develop alternative therapeutic strategies. Here, we show that human Vγ9Vδ2 T cells expanded by the aminobisphosphonate pamidronate (PAM) kill influenza virus-infected cells and inhibit viral replication in vitro. In Rag2(-/-)γc(-/-) immunodeficient mice reconstituted with human peripheral mononuclear cells (huPBMCs), PAM reduces disease severity and mortality caused by human seasonal H1N1 and avian H5N1 influenza virus, and controls the lung inflammation and viral replication. PAM has no such effects in influenza virus-infected Rag2(-/-)γc(-/-) mice reconstituted with Vγ9Vδ2 T cell-depleted huPBMCs. Our study provides proof-of-concept of a novel therapeutic strategy for treating influenza by targeting the host rather than the virus, thereby reducing the opportunity for the emergence of drug-resistant viruses. As PAM has been commonly used to treat osteoporosis and Paget's disease, this new application of an old drug potentially offers a safe and readily available option for treating influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.